The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial
Abstract
OBJECTIVE: This international, multicenter double-blind trial was designed to compare the therapeutic profile of an atypical antipsychotic, olanzapine, with that of a conventional dopamine D2 antagonist, haloperidol. METHOD: A total of 1,996 patients at 174 sites in Europe and North America were randomly assigned to treatment with olanzapine (N = 1,336) or haloperidol (N = 660) over 6 weeks. The primary efficacy analysis involved the mean change from baseline to endpoint in total scores on the Brief Psychiatric Rating Scale (BPRS). Secondary analyses included comparisons of the mean change in positive and negative symptoms, comorbid depression, extrapyramidal symptoms, and overall drug safety. RESULTS: Olanzapine demonstrated clinical results superior to those of haloperidol on overall improvement according to the BPRS and on every secondary measure, including depression. Olanzapine was also associated with significantly fewer discontinuations of treatment due to lack of drug efficacy or adverse events. Substantially more olanzapine-treated patients (66.5%) than haloperidol-treated patients (46.8%) completed 6 weeks of therapy. Statistically significant advantages of olanzapine treatment were related to 1) change in negative symptoms, 2) extrapyramidal symptom profile, 3) effect on prolactin levels, and 4) response rate. CONCLUSIONS: Olanzapine shows a superior and broader spectrum of efficacy in the treatment of schizophrenic psychopathology, with a substantially more favorable safety profile, than haloperidol. It meets several of the criteria for a novel atypical antipsychotic agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
U.S. Department of Health and Human Services
(2006) · Encyclopedia of Sexual Behavior and the Law · doi:10.4135/9781452240107.n226 · Cited by 3,170
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,062
The Two-syndrome Concept: Origins and Current Status
Crow, T. J. (1985) · Schizophrenia Bulletin · doi:10.1093/schbul/11.3.471 · Cited by 839
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., & Hamilton, S. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 778
One hundred years of schizophrenia: a meta-analysis of the outcome literature
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1409 · Cited by 762
Breier, A. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810270051007 · Cited by 626
Peuskens, J. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.6.712 · Cited by 551
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
Beasley, C. M., Sanger, T., Satterlee, W., Tollefson, G., Tran, P., & Hamilton, S. (1996) · Psychopharmacology · doi:10.1007/bf02245617 · Cited by 390
Symptoms, signs, and diagnosis of schizophrenia
Andreasen, N. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91325-4 · Cited by 344
Kane, J. M. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.1.133 · Cited by 323
Beasley, C. M., Hamilton, S. H., Crawford, A. M., Dellva, M. A., Tollefson, G. D., Tran, P. V., Blin, O., & Beuzen, J.-N. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00392-6 · Cited by 277
Kane, J. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340109 · Cited by 272
Clozapine: neuroleptic-induced EPS and tardive dyskinesia
Casey, D. E. (1989) · Psychopharmacology · doi:10.1007/bf00442559 · Cited by 251
Antipsychotic agents antagonize non-competitiveN-methyl-d-aspartate antagonist-induced behaviors
Corbett, R., Camacho, F., Woods, A. T., Kerman, L. L., Fishkin, R. J., Brooks, K., & Dunn, R. W. (1995) · Psychopharmacology · doi:10.1007/bf02246146 · Cited by 248
Clozapine-induced weight gain: prevalence and clinical relevance
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.1.68 · Cited by 248
Dr. Meltzer and Mr. Cola Reply
Meltzer, H. Y., & Cola, P. A. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.1.153 · Cited by 139
A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects
Nyberg, S. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00218-7 · Cited by 135
Stockton, M. E., & Rasmussen, K. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00130-r · Cited by 120
Pilowsky, L. S., Busatto, G. F., Taylor, M., Sharma, T., Sigmundsson, T., Costa, D. C., Ell, P. J., & Nohria, V. (1996) · Psychopharmacology · doi:10.1007/bf02245615 · Cited by 120
New antipsychotics: the present status
Gerlach, J., & Peacock, L. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199509000-00006 · Cited by 119
Clozapine: is another view valid?
Meltzer, H. Y. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.6.821 · Cited by 95
Neurocircuitries and neurotransmitter interactions in schizophrenia
Carlsson, A. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199509000-00004 · Cited by 75
Metabolism of Clozapine† by Neutrophils
Uetrecht, J. (1992) · Drug Safety · doi:10.2165/00002018-199200071-00011 · Cited by 70
Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo
Hemrick-Luecke, S. K., Snoddy, H. D., & Fuller, R. W. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00739-x · Cited by 46
Cytotoxic effects of neuroleptic drugs
Munyon, W., Salo, R., & Briones, D. F. (1987) · Psychopharmacology · doi:10.1007/bf00217059 · Cited by 36
Cytotoxicity of Phenothiazines on Chang Liver Cells as Measured by Enzyme Leakage
Dujovne, C. A., & Zimmerman, H. J. (1969) · Experimental Biology and Medicine · doi:10.3181/00379727-131-33931 · Cited by 27
Cited by
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
LEUCHT, S., KANE, J., KISSLING, W., HAMANN, J., ETSCHEL, E., & ENGEL, R. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.008 · Cited by 1,226
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1997-04-01
- Volume
- 154
- Issue
- 4
- Pages
- 457-465
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1787454655
- Cited by
- 891
- References
- 31
- FWCI
- 72.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.